New Key announces positive results for new drug Revlidomide in Phase 3 clinical trial OF EM

inert lymphoma refers to slow-spreadly lymphoma, a non-Hodgkin's lymphoma (NHL) type that accounts for about 40 percent of the NHLrecently,, a newcompany, announced positive results from thenew drugin a phase 3 clinicaltrial
study showed that Revlimid combined with Roche's Rituxan (rituximab, ritoxima) (R2) and had a significant advantage over single Rituxan in second-line treatment for patients with flistic lymphoma (FL) and marginal lymphoma (MZL)About Revlimid
Revlimid, an immunomodulator developed by New Base, has beenFDA (approved for the treatment of multiple myeloma (MM) and other cancersRituxan is a CD20 monoclonal antibody that is used to treat autoimmune diseases and several cancers, including CD20-positive NHL's study of Revlimid found that it enhances antibody-mediated cytotoxicity, thereby improving the effectiveness of antibodydrugSo the company uses Adlimid in combination with Rituxan in an effort to enhance the treatment of THE NHLThe OF the study, AUGMENT, is a multicenter, double-blind, randomized 3-phase study of FL and MZL patients who have received at least one full-body treatment who have relapsed or are difficult to treat but respond to Rituxan They were randomly assigned on a 1:1 scale and treated with R2 or Rituxan for up to a year the main endpoint of the study was the Non-Progress Ingest (PFS) assessed by the Independent Review Board (IRC) Secondary endpoints include total remission rate (ORR), total remission rate (CR), mitigation duration (DOR), duration of treatment to the next anti-lymphoma (TTNLT), total lifetime (OS), and safety results show edgy PFS in The R2 group is 39.4 months, while the median PFS in the Rituxan group is only 14.1 months The combination therapy reduced the risk of progression or death by 54% in the R2 group, more patients responded to treatment, with ORR reaching 78% compared to 53% in the Rituxan group CR results in both groups were 34% and 18%, respectively The median DOR results were 36.6 months and 21.7 months, respectively In addition, no new security signals were found these results suggest that R2 is expected to play an important role as a second-line therapy for this type of patient